bs-15583R-BF647 [Conjugated Primary Antibody]
TEM8 Polyclonal Antibody, AbBy Fluor® 647 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: TEM8

Immunogen Range: 201-300/564


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 84168

Swiss Prot: Q9H6X2

Source: KLH conjugated synthetic peptide derived from human TEM8

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

This gene encodes a type I transmembrane protein and is a tumor-specific endothelial marker that has been implicated in colorectal cancer. The encoded protein has been shown to also be a docking protein or receptor for Bacillus anthracis toxin, the causative agent of the disease, anthrax. The binding of the protective antigen (PA) component, of the tripartite anthrax toxin, to this receptor protein mediates delivery of toxin components to the cytosol of cells. Once inside the cell, the other two components of anthrax toxin, edema factor (EF) and lethal factor (LF) disrupt normal cellular processes. Three alternatively spliced variants that encode different protein isoforms have been described. [provided by RefSeq, Oct 2008]

Conjugation: AbBy Fluor® 647

Excitation/ Emission: 650nm/665nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 63


Cross Reactive Species: Human
Mouse

Predicted Cross Reactive Species: Rat
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Taguchi K et al. Isolation of tumor endothelial cells from murine cancer. (2018)Journal of Immunological Methods. Nov 3.Read more>>
  • Minmin Wang. et al. Infectious recombinant Senecavirus A expressing novel reporter proteins. 2021 Mar 03Read more>>
VALIDATION IMAGES